Search results for "static"

showing 10 items of 1528 documents

Cyclophosphamide plus Epidoxorubicin and 5-Fluorouracil with Folinic Acid as a Novel Treatment in Metastatic Breast Cancer: Preliminary Results of a …

1991

Twenty consecutive patients with advanced breast cancer were treated with a combination of cyclophosphamide 600 mg/m2 i.v. on day 1, epidoxorubicin 75 mg/m2 on day 1, and 5-fluorouracil 375 mg/m2 i.v. with folinic acid 200 mg/m2 i.v. on days 1----3. The overall response rate was 60%, with 10% of patients showing a complete response with a mean duration of 11.1 + months, and 50% of patients a partial response of 7.4 + months. A stabilization of 5.2 + months was obtained in 20% of cases, while 20% of patients progressed. The most frequently observed toxicity was leukopenia, while expected mucosal toxicities were rather mild.

Adult0301 basic medicinemedicine.medical_specialtyCyclophosphamide030106 microbiologyLeucovorinPhases of clinical researchBreast NeoplasmsGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideEpirubicinPharmacologyLeukopeniabusiness.industryRemission InductionCancerMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisDrug EvaluationFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Relationship of Flow Rate with Symptoms, Quality of Life and Other Clinical Parameters in Patients with LUTS Suggestive of BPH

2001

The uroflowmetry data of a selected number of patients who took part to the QUIBUS study (366 traces selected after quality control by a central panel of reviewer) were evaluated for their relationships with age, prostate volume, and IPSS and ICS-BPH scores. Waiting time, flow time, voided volume, maximum flow rate (Q(max)) and average flow rate (Q(ave)) were the flow variables considered for analysis. Only measurements with total voided volume exceeding 100 ml were included.An increasing percentage of subjects with voided volume200 ml was observed over 65 years of age. Age did not affect neither Q(ave) nor Q(max )(p = n.s. at correlation analysis). In particular, Q(max)was15 ml/s in about …

AdultAged 80 and overMaleGynecologymedicine.medical_specialtybusiness.industryUrologyProstatic HyperplasiaMiddle AgedUrination Disordersmedicine.diseaseUrodynamicsQuality of lifeLower urinary tract symptomsInternal medicineEpidemiologyQuality of LifemedicineHumansProstate diseaseProstatismIn patientbusinessAgedEuropean Urology
researchProduct

MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.

2007

Background: The clinical significance of the circulating levels of activin A and matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) was investigated in patients with breast cancer (BC) or prostate cancer (PC) with (M1) or without (M0) bone metastasis. Patients and Methods: MMP-2, MMP-9 and activin A blood concentrations were measured by enzyme immunoassays in 79 cancer patients and in 57 healthy blood donors (HS) who served as a control group. The diagnostic accuracy of these molecules to discriminate between M0 and M1 patients was evaluated by the receiver operating characteristic curve (ROC) and compared to that of tumor markers CA15.3 or prostate-specific antigen (PSA). Results: Activin A…

AdultAged 80 and overMaleMucin-1Prostatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedActivinsActivin Breast Cancer Bone metastasis proteinasesMatrix Metalloproteinase 9Activins; Adult; Aged; Aged 80 and over; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Mucin-1; Prostatic NeoplasmsHumansMatrix Metalloproteinase 2FemaleAged
researchProduct

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor s…

1997

Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressively escalated by 2 mg/m2/cycle up to 18 mg/m2 in the absence of dose-limiting toxicities. Granulocyte colony stimulating factor (G-CSF) was given s.c. in order to prevent neutropenia. DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significa…

AdultAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentAntidotesLeucovorinAntineoplastic AgentsBreast NeoplasmsPharmacologyNeutropeniaGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicinePharmacology (medical)Antineoplastic Agents AlkylatingCyclophosphamideAgedPharmacologyMitoxantroneChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerGranulocyte colony-stimulating factorItalyOncologyToxicityAbsolute neutrophil countFemaleFluorouracilMitoxantronebusinessmedicine.drugAnti-Cancer Drugs
researchProduct

The utility of 3D medical imaging techniques for obtaining a reliable differential diagnosis of metastatic cancer in an Iron Age skull.

2018

Abstract In this report we present a case of neoplastic disease affecting an Iron Age skull that provides some of the earliest evidence of metastatic cancer (MC) in Western Europe. The cranium comes from the indigenous site of Baucina (Palermo, Sicily) and was recovered in a multiple burial context dated to the 6th–5th centuries BCE. The skull was attributed to an adult female and was characterized by numerous perforating lytic lesions. CT and 3D imaging analyses were crucial for obtaining a diagnosis of MC. Based on the morphology of the lytic lesions and the biological profile of our specimen, we can tentatively suggest breast carcinoma as the primary origin of the clinical manifestations…

AdultArcheologyPathologymedicine.medical_specialtyPaleopathologyPalaeopathology Osteolytic lesions 3D imaging Differential diagnosis Metastatic carcinomaContext (language use)Bone NeoplasmsSettore BIO/08 - Antropologia030218 nuclear medicine & medical imagingPathology and Forensic MedicineMetastatic carcinomaDiagnosis Differential03 medical and health sciences0302 clinical medicineImaging Three-DimensionalImage Interpretation Computer-AssistedMedical imagingmedicineHumans0601 history and archaeologyNeoplasm MetastasisPaleopathologyHistory Ancient060101 anthropologybusiness.industryFossilsCarcinomaSkullCancer06 humanities and the artsmedicine.diseaseSkullmedicine.anatomical_structureFemaleDifferential diagnosisBreast carcinomabusinessTomography X-Ray ComputedInternational journal of paleopathology
researchProduct

Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine

2019

BackgroundProstate cancer incidence varies internationally largely attributable to differences in prostate-specific antigen (PSA) use. The aim of this study was to provide the most recent detailed international epidemiological comparison of prostate cancer incidence and mortality in six north-eastern European countries (Belarus, Estonia, Latvia, Lithuania, the Russian Federation and Ukraine).MethodsThe number of incident prostate cancer cases was obtained from the countries national cancer registries. Prostate cancer mortality and corresponding population data were extracted from the WHO Mortality Database. Age-specific and age-standardised incidence and mortality rates were calculated (Eur…

AdultBaltic StatesMaletrendsmedicine.medical_specialtyRepublic of BelarusEpidemiology030232 urology & nephrologyPrevalenceRussia03 medical and health sciencesProstate cancer0302 clinical medicineProstateSyöpätaudit - CancersEpidemiologymedicineHumans1506AgedOriginal ResearchAged 80 and overProstate cancerbusiness.industryIncidenceIncidence (epidemiology)Mortality rateProstatic NeoplasmsCancerGeneral MedicineMiddle Agedmedicine.diseasemortality1692Prostate-specific antigenmedicine.anatomical_structure030220 oncology & carcinogenesisincidencePSA uptakeUkrainebusinessDemography
researchProduct

Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

1995

This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAI), and tissue plasminogen activator antigen basally (tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (< 40 years) obese subjects with central fat distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fas…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenVentricular Function LeftSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundEndocrinologyWaist–hip ratioInternal medicineFibrinolysismedicineHumansInsulinObesityHemostatic functionBlood CoagulationApolipoproteins ATriglyceridesApolipoproteins BHemostasisbiologybusiness.industryCholesterolCholesterol HDLFibrinogenCentral obesity Hemostatic function left ventricular functionPlasminogenFactor VIISettore MED/11 - Malattie Dell'Apparato CardiovascolarePlasminogen InactivatorsEndocrinologychemistrybiology.proteinBody ConstitutionRegression AnalysisFemalebusinessPlasminogen activatormedicine.drugLipoproteinMetabolism: clinical and experimental
researchProduct

Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals

2021

Abstract Objectives Insulin resistance (IR) is a hallmark of type 2 diabetes mellitus (DM). The homeostatic model assessment of insulin resistance (HOMA-IR) provides an estimate for IR from fasting glucose and insulin serum concentrations. The aim of this study was to obtain a reference interval for HOMA-IR for a specific insulin immunoassay. Methods The Gutenberg Health Study (GHS) is a population-based, prospective, single-center cohort study in Germany with 15,030 participants aged 35–74 years. Fasting glucose, insulin, and C-peptide were available in 10,340 participants. HOMA-IR was calculated in this group and three reference subgroups with increasingly more stringent inclusion criteri…

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryCohort StudiesInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansInsulinProspective StudiesPrediabetesAgedbusiness.industryInsulinBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseDiabetes Mellitus Type 2CohortHomeostatic model assessmentFemaleInsulin ResistanceMetabolic syndromebusinessCohort studyClinical Chemistry and Laboratory Medicine (CCLM)
researchProduct

Reversible effect of magnetic fields on human lymphocyte activation patterns: different sensitivity of naive and memory lymphocyte subsets.

2009

The aim of this study was to investigate the influence of 50 Hz magnetic or static magnetic fields of 0.5 mT on subsets of human CD4(+) T cells in terms of cytokine release/content, cell proliferation and intracellular free calcium concentration. CD4(+) T cells can be divided into different subsets on the basis of surface marker expression, such as CD45, and T cells can be divided into naive (CD45RA(+)) and memory (CD45RA(-)) cells. In this study, the effects of magnetic fields after 24 and 48 h of cell culture were analyzed. We found that the CD4(+)CD45RA(-) T subset were more sensitive after 2 h of exposure. Decreases in the release/content of IFN-gamma, in cell proliferation and in intra…

AdultCD4-Positive T-LymphocytesMaleTime Factorsmedicine.medical_treatmentBiophysicsBiologyLymphocyte ActivationInterferon-gammaMagneticsCytosolstatic magnetic fields CD4(+) T cells.T-Lymphocyte SubsetsmedicineHumansRadiology Nuclear Medicine and imagingCells CulturedCell ProliferationCalcium metabolismHuman lymphocyteRadiationCell growthMagnetic fieldCell biologyCytokineCell cultureImmunologyLeukocyte Common AntigensCalciumFemaleShort exposureImmunologic MemoryLymphocyte subsets
researchProduct

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

2011

Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy–based approach. Median age was 48 years (range: 30–83 years). Tumor subtype included 72% horm…

AdultCancer Researchmedicine.medical_specialtyClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Breast Neoplasmsmedicine.disease_causeArticleMetastasisMetastasisPhosphatidylinositol 3-KinasesBreast cancerInternal medicineBreast CancermedicinePTENHumansPTEN lossReceptorneoplasmsPI3K/AKT/mTOR pathwayAgedAged 80 and overMutationbiologyPTEN PhosphohydrolaseMiddle Agedmedicine.diseaseMetastatic breast cancerEndocrinologyOncologyReceptors EstrogenMutationbiology.proteinCancer researchImmunohistochemistryFemalePIK3CA mutationsReceptors ProgesteroneSignal TransductionMolecular cancer therapeutics
researchProduct